He earned an M.D. as well as a Ph.D. degree in Biochemistry from the University of Oviedo in Spain. Then he pursued postdoctoral training in synthetic biology at both Duke University and MIT, where he developed novel techniques for transcriptional regulation and biopharmaceutical production. Pablo’s current research primarily focuses on developing novel technologies for gene activation that can be applied for correction of genetic diseases.